Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy

Yueming Zhu, Angela Elizabeth Dean, Nobuo Horikoshi, Collin Heer, Douglas R. Spitz, David R Gius*

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Mammalian cells use a complex network of redox-dependent processes necessary to maintain cellular integrity during oxidative metabolism, as well as to protect against and/or adapt to stress. The disruption of these redox-dependent processes, including those in the mitochondria, creates a cellular environment permissive for progression to a malignant phenotype and the development of resistance to commonly used anticancer agents. An extension of this paradigm is that when these mitochondrial functions are altered by the events leading to transformation and ensuing downstream metabolic processes, they can be used as molecular biomarkers or targets in the development of new therapeutic interventions to selectively kill and/or sensitize cancer versus normal cells. In this Review we propose that mitochondrial oxidative metabolism is altered in tumor cells, and the central theme of this dysregulation is electron transport chain activity, folate metabolism, NADH/NADPH metabolism, thiol-mediated detoxification pathways, and redox-active metal ion metabolism. It is proposed that specific subgroups of human malignancies display distinct mitochondrial transformative and/or tumor signatures that may benefit from agents that target these pathways.

Original languageEnglish (US)
Pages (from-to)3682-3691
Number of pages10
JournalJournal of Clinical Investigation
Volume128
Issue number9
DOIs
StatePublished - Aug 31 2018

Fingerprint

Oxidation-Reduction
Neoplasms
Therapeutics
Electron Transport
NADP
Folic Acid
Sulfhydryl Compounds
Antineoplastic Agents
NAD
Mitochondria
Biomarkers
Metals
Ions
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zhu, Yueming ; Dean, Angela Elizabeth ; Horikoshi, Nobuo ; Heer, Collin ; Spitz, Douglas R. ; Gius, David R. / Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 9. pp. 3682-3691.
@article{02fe1c19e02b4ba9b12583d79c7cec01,
title = "Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy",
abstract = "Mammalian cells use a complex network of redox-dependent processes necessary to maintain cellular integrity during oxidative metabolism, as well as to protect against and/or adapt to stress. The disruption of these redox-dependent processes, including those in the mitochondria, creates a cellular environment permissive for progression to a malignant phenotype and the development of resistance to commonly used anticancer agents. An extension of this paradigm is that when these mitochondrial functions are altered by the events leading to transformation and ensuing downstream metabolic processes, they can be used as molecular biomarkers or targets in the development of new therapeutic interventions to selectively kill and/or sensitize cancer versus normal cells. In this Review we propose that mitochondrial oxidative metabolism is altered in tumor cells, and the central theme of this dysregulation is electron transport chain activity, folate metabolism, NADH/NADPH metabolism, thiol-mediated detoxification pathways, and redox-active metal ion metabolism. It is proposed that specific subgroups of human malignancies display distinct mitochondrial transformative and/or tumor signatures that may benefit from agents that target these pathways.",
author = "Yueming Zhu and Dean, {Angela Elizabeth} and Nobuo Horikoshi and Collin Heer and Spitz, {Douglas R.} and Gius, {David R}",
year = "2018",
month = "8",
day = "31",
doi = "10.1172/JCI120844",
language = "English (US)",
volume = "128",
pages = "3682--3691",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "9",

}

Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. / Zhu, Yueming; Dean, Angela Elizabeth; Horikoshi, Nobuo; Heer, Collin; Spitz, Douglas R.; Gius, David R.

In: Journal of Clinical Investigation, Vol. 128, No. 9, 31.08.2018, p. 3682-3691.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy

AU - Zhu, Yueming

AU - Dean, Angela Elizabeth

AU - Horikoshi, Nobuo

AU - Heer, Collin

AU - Spitz, Douglas R.

AU - Gius, David R

PY - 2018/8/31

Y1 - 2018/8/31

N2 - Mammalian cells use a complex network of redox-dependent processes necessary to maintain cellular integrity during oxidative metabolism, as well as to protect against and/or adapt to stress. The disruption of these redox-dependent processes, including those in the mitochondria, creates a cellular environment permissive for progression to a malignant phenotype and the development of resistance to commonly used anticancer agents. An extension of this paradigm is that when these mitochondrial functions are altered by the events leading to transformation and ensuing downstream metabolic processes, they can be used as molecular biomarkers or targets in the development of new therapeutic interventions to selectively kill and/or sensitize cancer versus normal cells. In this Review we propose that mitochondrial oxidative metabolism is altered in tumor cells, and the central theme of this dysregulation is electron transport chain activity, folate metabolism, NADH/NADPH metabolism, thiol-mediated detoxification pathways, and redox-active metal ion metabolism. It is proposed that specific subgroups of human malignancies display distinct mitochondrial transformative and/or tumor signatures that may benefit from agents that target these pathways.

AB - Mammalian cells use a complex network of redox-dependent processes necessary to maintain cellular integrity during oxidative metabolism, as well as to protect against and/or adapt to stress. The disruption of these redox-dependent processes, including those in the mitochondria, creates a cellular environment permissive for progression to a malignant phenotype and the development of resistance to commonly used anticancer agents. An extension of this paradigm is that when these mitochondrial functions are altered by the events leading to transformation and ensuing downstream metabolic processes, they can be used as molecular biomarkers or targets in the development of new therapeutic interventions to selectively kill and/or sensitize cancer versus normal cells. In this Review we propose that mitochondrial oxidative metabolism is altered in tumor cells, and the central theme of this dysregulation is electron transport chain activity, folate metabolism, NADH/NADPH metabolism, thiol-mediated detoxification pathways, and redox-active metal ion metabolism. It is proposed that specific subgroups of human malignancies display distinct mitochondrial transformative and/or tumor signatures that may benefit from agents that target these pathways.

UR - http://www.scopus.com/inward/record.url?scp=85052552824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052552824&partnerID=8YFLogxK

U2 - 10.1172/JCI120844

DO - 10.1172/JCI120844

M3 - Review article

VL - 128

SP - 3682

EP - 3691

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 9

ER -